Alendronate Sodium 121268-17-5
Alendronic acid (INN) or alendronate sodium (USAN, sold as Fosamax by Merck) is a bisphosphonate drug used for osteoporosis and several other bone diseases. It is marketed alone as well as in combination with vitamin D (2,800 U and 5600 U, under the name Fosamax+D). Merck's U.S. patent on alendronate expired in 2008 and Merck lost a series of appeals to block a generic version of the drug from being certified by the U.S. Food and Drug Administration (FDA).
| Systematic (IUPAC) name: |
sodium[4-amino-1-hydroxy-1-(hydroxy-oxido-phosphoryl)-butyl]phosphonicacidtrihydrate |
| Alendronate Sodium CAS number: |
121268-17-5 |
| ATC code: |
M05BA04 |
| PubChem: |
2088 |
| DrugBank: |
APRD00561 |
| Formula: |
C4H18NNaO10P2 |
| Molecular mass: |
325.124 g/mol |
| Alendronate Sodium Assay/Purity: |
Typically NLT 98% |
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
